Pharma

Your Article Summary

See Latest Articles

Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Corporate News Releases - The Healthcare Sales & Marketing Network, 03/11/08

Women may reduce the risk of their breast cancer returning by starting treatment with Femara anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology(1).The exploratory analysis of post-unblinding results from the landmark MA-17 trial, led by the National Cancer Institute of Canada Clinical Trials Group, evaluated a subset of women in the original placebo group when the study was unblinded.

Today in Physician/Patient Trends...keeping you current

Receive free subspecialty "5-minute updates" via email

Trends in hypertension treatment in diabetes
Current Hypertension Reports, 12/09/09

New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health
Daiichi Sankyo, 12/08/09

Surgical and minimally invasive treatments for Peyronie's disease
Current Opinion in Urology, 11/19/09

 See all of Physician/Patient Trends

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche, 12/14/09

Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche, 12/14/09

ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium
ImmunoGen, Inc., 12/14/09

 See all of Research & Development